Current Regional Anesthesia Guidelines: A Summary with Clinical Insights

scribeofegypt@gmail.com infographs April 16, 2026April 17, 2026Guidelines, Infographic, Regional anesthesia, ultrasound-guided regional anesthesia

Current Regional Anesthesia Guidelines: A Summary with Clinical Insights

1. Antithrombotic/Anticoagulant Management (ASRA Pain Medicine, 5th Edition)

The infographic highlights the critical balance between preventing spinal hematoma and thromboembolic risk in patients on anticoagulation therapy.

Clinical Insights:

Patients who receive anticoagulation therapy — used to treat or prevent embolic complications from conditions like atrial fibrillation or deep vein thrombosis — face an increased risk of bleeding and complications during regional anesthesia procedures such as spinal, epidural, or nerve blocks. Newswise

The 5th edition of the ASRA guidelines reviews published evidence since 2018 and provides guidance to help avoid potentially catastrophic hemorrhagic complications, which, while extremely rare, remain a serious concern. Guideline Central

Because the rarity of spinal hematoma makes prospective randomized study impossible, these consensus statements represent the collective experience of recognized experts, based on case reports, clinical series, pharmacology, hematology, and risk factors for surgical bleeding — each with appropriate grading of evidence. ASRA Pain Medicine

Key practices include:

Drug-specific stopping times to allow plasma clearance before procedures
Bridging therapy decisions for high-risk patients
Balancing risk of spinal hematoma vs. thromboembolism on a patient-by-patient basis

📚 Reference: Kopp SL, Vandermeulen E, McBane RD, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA Evidence-Based Guidelines (5th edition). Reg Anesth Pain Med. 2025. doi:10.1136/rapm-2024-105766

2. Infection Control Guidelines

The infographic recommends strict aseptic technique, chlorhexidine/alcohol disinfection, surgical masks, gloves, sterile drapes, and minimizing skin flora.

Clinical Insights:

Skin preparation with chlorhexidine is preferred over povidone-iodine prior to block placement. A tunneled catheter technique is suggested when the caudal route is used or if the epidural catheter is kept in situ for more than 3 days. Inspection of the epidural catheter insertion site should be performed at least once daily as part of postoperative management. ScienceDirect

In children undergoing regional anesthesia, the incidence of infection, hematoma, and local anesthetic toxicity is low when strict adherence to aseptic technique is maintained. PubMed

📚 Reference: ASRA/ESRA Joint Committee. Practice Advisory on Prevention and Management of Complications of Pediatric Regional Anesthesia. Journal of Clinical Anesthesia, 2022. doi:10.1016/j.jclinane.2022.110726

3. Ultrasound Guidance Recommendations

The infographic strongly endorses ultrasound-guided regional anesthesia (UGRA) for identifying anatomical landmarks, visualizing nerves and vessels, and reducing accidental vascular injection.

Clinical Insights:

Direct visualization of local anesthetic distribution with high-frequency probes can improve the quality of blocks and avoid complications of both upper/lower extremity nerve blocks and neuraxial techniques. Ultrasound guidance enables the anesthetist to secure accurate needle positioning and monitor local anesthetic spread in real time — offering significant advantages over conventional nerve stimulation and loss-of-resistance techniques. PubMed

Dexamethasone is the most effective adjunct in UGRA; studies show it helps maintain pain relief longer, particularly with erector spinae and serratus anterior plane blocks. Adding dexmedetomidine to ropivacaine improves pain relief and recovery, though it raises the risk of sedation and bradycardia. Cureus

📚 Reference: Jamaleddin Ahmad FA, Herrera JA, Saldanha JM, et al. Ultrasound-Guided Regional Anesthesia: A Narrative Review of Techniques, Safety, and Clinical Applications. Cureus. 2026;18(2):e102822. doi:10.7759/cureus.102822

4. Pediatric Regional Anesthesia Safety

The infographic emphasizes unique pediatric physiology, the “Rule of 25” for weight-based dosing, sedation management, and specialized monitoring for local anesthetic systemic toxicity (LAST).

Clinical Insights:

The ASRA/ESRA Joint Committee recommends that spinal anesthesia with bupivacaine can be performed using a dose of 1 mg/kg for newborns and infants, and 0.5 mg/kg in older children above 1 year of age, based on a systematic evidence review. PubMed

Maximum doses of local anesthetics should be calculated in advance, and doses required should be drawn up along with appropriate additive medications before the procedure begins. Chlorhexidine is the most commonly used agent for skin disinfection, and blunt-tip echogenic needles should be used for most peripheral nerve blocks. NCBI

Ultrasound-guided peripheral nerve blocks reduce the risk of vascular puncture and therefore reduce the risk of local anesthetic toxicity in pediatric patients. ScienceDirect

Ultrasound guidance, in use for approximately two decades now, has greatly improved the effectiveness and reliability of pediatric regional techniques. Today, pediatric regional anesthesia has an excellent safety profile, with reports on complications being anecdotal. PubMed Central

📚 References:

ASRA/ESRA Joint Committee. Local Anesthetics and Adjuvants Dosage in Pediatric Regional Anesthesia. Reg Anesth Pain Med. 2018. doi:10.1097/AAP.0000000000000702
StatPearls: Pediatric Regional Anesthesia. NCBI Bookshelf. 2023. ncbi.nlm.nih.gov/books/NBK572106

5. Safety, Monitoring & Multimodal Analgesia

The final section covers opioid-sparing strategies, postoperative neurological monitoring, and promoting regional techniques within multimodal analgesia plans.

Clinical Insights:

Regional anesthesia is now a cornerstone of multimodal analgesia protocols. By incorporating nerve blocks and neuraxial techniques alongside NSAIDs, acetaminophen, and gabapentinoids, clinicians can substantially reduce opioid consumption and its associated side effects (nausea, respiratory depression, chronic dependence). Early mobilization — facilitated by effective regional analgesia — has also been linked to improved surgical outcomes and shorter hospital stays.

Careful postoperative neurological monitoring is essential to detect rare but serious complications such as epidural hematoma, nerve injury, or delayed LAST. Any new neurological deficit following a regional technique warrants urgent investigation.

📚 Reference: Rawal N. Current issues in postoperative pain management. Eur J Anaesthesiol. 2016;33(3):160–171.

Overall Takeaway

This infographic reflects a patient-centered, evidence-based approach to regional anesthesia, integrating anticoagulation safety, infection prevention, ultrasound technology, pediatric-specific protocols, and opioid-sparing multimodal strategies. The cornerstone reference throughout is the ASRA Pain Medicine 5th Edition Guidelines (2025), which represents the current gold standard for safe regional anesthetic practice globally.

Navigating the 2026 AHA-ACC Guidelines for Acute Pulmonary Embolism

scribeofegypt@gmail.com infographs, Scribe medical conferences Egypt March 7, 2026March 7, 2026Guidelines, Infographic, PE, Pulmonary Embolism

Navigating the 2026 AHA-/ACC Guidelines for Acute Pulmonary Embolism

2026-AHA-ACC-Guidelines-for-Acute-Pulmonary-Embolism-

Overview

The 2026 AHA/ACC Guidelines introduce a landmark restructuring of how acute pulmonary embolism is diagnosed, risk-stratified, and managed. Central to these guidelines is a new five-category clinical classification system (A–E) that replaces older binary or ternary risk frameworks, enabling more granular, individualized treatment pathways.

Phase 1: Diagnosis & Assessment

Step 1 – Clinical Suspicion & Screening

Use the YEARS criteria or age-adjusted D-dimer to assess pretest probability in low/intermediate-risk patients
Goal: determine which patients require definitive imaging

Step 2 – Definitive Imaging

CT Pulmonary Angiography (CTPA) remains the gold-standard imaging modality
CTPA is recommended even in pregnancy for high-probability presentations

Step 3 – Risk Stratification

Immediately classify patients into one of five AHA/ACC Clinical Categories (A–E)
This replaces the older low/intermediate/high-risk triage schema

Phase 2: The New Clinical Categories (A–E)

The following table summarizes the five new clinical categories and their key distinguishing features:

Category	Clinical Features	Risk Level
A – Subclinical	Asymptomatic or incidental PE. Safe for outpatient management from ED.	Lowest
B – Symptomatic / Low Severity	Low clinical severity scores. Early hospital discharge generally recommended.	Low
C – Elevated Clinical Severity	Elevated severity scores. Requires hospitalization (e.g., RV dysfunction, elevated troponin/BNP).	Intermediate-High
D – Incipient Cardiopulmonary Failure	Transient hypotension or normotensive shock. Requires hospitalization and advanced therapies.	High
E – Cardiopulmonary Failure	Full cardiopulmonary failure, persistent hypotension. Requires critical care and immediate advanced therapy.	Highest

Phase 3: Acute Management & Advanced Interventions

Anticoagulation Standard

First-line agents: DOACs (Direct Oral Anticoagulants):
DOACs are now preferred over Vitamin K Antagonists (VKAs) for most patients
LMWH (Low Molecular Weight Heparin) is preferred over UFH (Unfractionated Heparin) for parenteral therapy

Advanced Therapies (High-Risk Categories D & E)

Systemic Thrombolysis – “Reasonable” to consider in appropriate candidates
Catheter-Directed Thrombolysis (CDT) – Targeted delivery of thrombolytics
Mechanical Thrombectomy (MT) – Indicated when thrombolysis is contraindicated or fails

Multidisciplinary PE Response Teams (PERTs)

Strongly recommended for Categories C, D, and E
PERTs enable expedited, coordinated, specialist-level care decisions
Involvement of cardiology, pulmonology, hematology, interventional radiology, and critical care

Special Populations

VKAs remain the standard of care for Antiphospholipid Syndrome (APS) patients
Particularly important for patients with arterial thrombosis or triple-antibody positivity
Individualized risk-benefit assessment is essential in pregnancy and renal impairment

Phase 4: Post-Acute Care & The ‘Long Game’

7-Day Follow-Up

Clinical visit within one week of discharge
Check DOAC adherence, assess access to medications, and monitor for bleeding

3–6 Month Reassessment

Determine duration of anticoagulation therapy based on clinical risk factors
Continue beyond 6 months for first PE without a major reversible provoking risk factor

CTEPD Screening (Chronic Thromboembolic Pulmonary Disease)

Screen all patients for CTEPD at every follow-up visit
For >1 year post-PE: screen if persistent dyspnea or functional impairment is present
Early identification allows referral for surgical or balloon pulmonary angioplasty

Key Clinical Insights

What’s Changed vs. Prior Guidelines

A–E framework replaces the traditional massive / submassive / low-risk classification, allowing far more tailored decision-making
DOACs are now explicitly preferred first-line — a definitive shift away from warfarin for the general PE population
Category A (Subclinical) legitimizes outpatient management from the ED for asymptomatic/incidental PE, reducing unnecessary hospitalization
PERT is now broadly endorsed across three categories (C–E), elevating its standard-of-care status

Practical Takeaways for Clinicians

Classify early: Assign A–E category at the time of diagnosis to guide all downstream decisions
Don’t over-admit: Category A and B patients may be safely discharged with appropriate anticoagulation and timely follow-up
Don’t under-treat: Categories D and E warrant aggressive, immediate intervention — delays worsen outcomes
Think long-term: The ‘long game’ framework emphasizes CTEPD screening and anticoagulation duration decisions as equally important as acute management
Involve the team: For complex or high-risk cases, activate PERT early — multidisciplinary input improves outcomes

Unanswered Questions & Areas of Ongoing Research

Optimal patient selection for CDT vs. MT in Category D/E remains an active research area
Role of extended anticoagulation in unprovoked PE patients with intermediate bleeding risk
Long-term outcomes data for Category A patients managed entirely as outpatients

A New ERA in Type 2 DIABETES MANAGEMENT – NICE 2025 -2026 Guidelines

scribeofegypt@gmail.com Scribe medical conferences Egypt February 28, 2026March 3, 2026GLP-1 receptor agonist, Guidelines, individualised HbA1c targets, Infographic, SGLT2 inhibitors (SGLT2i), Type 2 Diabetes

A New ERA in Type 2 DIABETES MANAGEMENT – NICE 2025-2026 Guidelines

A New ERA in Type 2 DIABETES MANAGEMENT - NICE 2025-2026 Guidelines

The Core Paradigm Shift

The most fundamental change in these guidelines is the move away from glucose-centric care (simply hitting HbA1c targets) toward cardio-renal protection — actively preventing heart failure, cardiovascular events, and kidney disease progression. This reflects decades of outcome trial data showing that glycaemic control alone does not sufficiently reduce macrovascular risk.

Universal First-Line Therapy

The guidelines now recommend SGLT2 inhibitors (SGLT2i) for most adults, even those without established cardiovascular disease or obesity — a significant broadening of their use. The standard initial regimen is:

Metformin MR + SGLT2 inhibitor from the outset, with a preference for modified-release Metformin to improve GI tolerability.

Clinical Insight: This represents a move from a stepwise “add-on” approach to earlier combination therapy, acknowledging that waiting for complications to develop before intensifying treatment is clinically inadequate.

Priority Patient Profiles

The guidelines stratify management by comorbidity:

Atherosclerotic CVD (ASCVD): Aggressive triple therapy from the start — Metformin MR + SGLT2i + subcutaneous Semaglutide. This combination addresses glucose, weight, cardiovascular inflammation, and renal endpoints simultaneously.

Heart Failure (any ejection fraction): Metformin MR + SGLT2i is the backbone. Notably, Pioglitazone is strictly contraindicated due to fluid retention risk — an important safety red flag for clinicians.

Chronic Kidney Disease (CKD): When eGFR is 20–30, a DPP-4 inhibitor is offered alongside Dapagliflozin or Empagliflozin specifically to preserve residual renal function. The choice of SGLT2i here is evidence-based on the DAPA-CKD and EMPA-KIDNEY trials.

Clinical Insight: The differentiation by comorbidity moves away from a “one-size-fits-all” protocol and demands that clinicians actively screen for cardiac and renal status at diagnosis.

The Early-Onset Pathway (Age <40) — Major Change

This is one of the most clinically significant new additions. Younger patients face higher lifetime cardiovascular risk and faster disease progression, so the guidelines now recommend:

Initial triple consideration: Metformin + SGLT2i
Early addition of a GLP-1 receptor agonist or Tirzepatide to reach glycaemic targets faster and protect against early cardiovascular events

Clinical Insight: Tirzepatide (a dual GIP/GLP-1 agonist) being explicitly mentioned reflects its superior HbA1c and weight reduction data. For younger patients, aggressive early intervention may delay or prevent the complications that drive long-term morbidity and mortality.

Safety & Monitoring — Key Alerts

Two critical safety points stand out:

Sick Day Rules: Metformin and SGLT2i should be suspended during acute illness to prevent dehydration and euglycaemic ketoacidosis — a protocol that must be clearly communicated to patients.

DKA Risk: If blood ketones exceed 1.0–3.0 mmol/L, SGLT2i must be stopped immediately and urgent medical attention sought. Euglycaemic DKA remains an underrecognised risk with SGLT2i use.

“Do Not Mix” Rule: GLP-1 receptor agonists and DPP-4 inhibitors should never be prescribed together due to therapeutic overlap — both act on the incretin pathway, making combination use redundant and potentially harmful.

Shared Decision Making & Lifestyle

The guidelines emphasise individualised HbA1c targets based on age, comorbidities, and side effect profiles rather than universal targets. Language around weight and lifestyle should be non-judgmental and non-stigmatising, and remission through low-carb/low-energy diets should be actively supported as a realistic goal.

Overall Clinical Takeaway

These guidelines represent a maturation of T2DM management into a multi-organ protection strategy. Clinicians need to shift their mindset from “lower the glucose” to “protect the heart and kidneys first.” SGLT2 inhibitors are now the cornerstone drug class across nearly all patient profiles, with GLP-1/GIP agonists playing an increasingly prominent role — particularly in younger, higher-risk, and ASCVD populations.